Clinical medicine

Median Technologies Announces Outstanding Performance for its iBiopsy® Lung Cancer Screening CADx1 to Accurately Characterize Malignant vs Benign Lung Nodules Based on a Large-scale Patient Cohort

Retrieved on: 
Monday, September 6, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Medicine, Lung cancer, Medical tests, Clinical medicine, Health, Radiology, Lung nodule, Screening, Cancer screening, Cancer, CT scan, Oncology

Median Technologies (Paris:ALMDT) (ALMDT:PA) announces outstanding performance based on a large-scale lung cancer screening (LCS) patient cohort to characterize malignant vs benign lung nodules based on a deep learning algorithm on low-dose chest computed tomography.

Key Points: 
  • Median Technologies (Paris:ALMDT) (ALMDT:PA) announces outstanding performance based on a large-scale lung cancer screening (LCS) patient cohort to characterize malignant vs benign lung nodules based on a deep learning algorithm on low-dose chest computed tomography.
  • The Median Technologies iBiopsy Lung Cancer Development Plan was launched in February 2021 , as part of the Companys strategic positioning in early-stage disease diagnosis.
  • Major international studies have shown that LDCT lung cancer screening can reduce mortality by 44% (NELSON Trial, 2018).
  • The study was based on a cohort of 1,696 patients from the National Lung Screening Trial cases (NLST) consisting of a total of 15,608 lung nodules.

Poxel Announces Its Participation at Investor and Scientific Conferences in September

Retrieved on: 
Monday, September 6, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Medical specialties, Clinical medicine, Health, Hepatitis, Steatohepatitis, Non-alcoholic fatty liver disease, Sumitomo Dainippon Pharma, Adrenoleukodystrophy, Thiazolidinedione

POXEL SA (Euronext POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced its participation at upcoming investor and scientific conferences in September 2021.

Key Points: 
  • POXEL SA (Euronext POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced its participation at upcoming investor and scientific conferences in September 2021.
  • Thomas Kuhn, CEO, will present the company, and Poxel management team members will be available for one-on-one virtual meetings.
  • Poxel has clinical and earlier-stage programs from its adenosine monophosphate-activated protein kinase (AMPK) activator and deuterated TZD platforms targeting chronic and rare metabolic diseases.
  • Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

Metabolic Changes in Plasma and Immune Cells Are Associated with COVID-19 Severity and May Predict Patient Survival, Institute for Systems Biology (ISB) Study Shows

Retrieved on: 
Monday, September 6, 2021
Health, Infectious Diseases, Genetics, Clinical Trials, General Health, Biotechnology, Branches of biology, Medical specialties, Clinical medicine, Cancer immunotherapy, COVID-19, T helper cell, Immunotherapy, Immune system, Immunometabolism, La Jolla Institute for Immunology

Researchers from Institute for Systems Biology (ISB), Fred Hutchinson Cancer Research Center and other organizations have uncovered underlying metabolic changes that regulate how immune cells react to COVID-19.

Key Points: 
  • Researchers from Institute for Systems Biology (ISB), Fred Hutchinson Cancer Research Center and other organizations have uncovered underlying metabolic changes that regulate how immune cells react to COVID-19.
  • After examining the blood samples from nearly 200 COVID-19 patients, researchers have uncovered underlying metabolic changes that regulate how immune cells react to the disease.
  • These changes are associated with disease severity and could be used to predict patient survival.
  • The deeper understanding gained here may eventually lead to better therapies that can more precisely target the most problematic immune or metabolic changes.

Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit

Retrieved on: 
Sunday, September 5, 2021
Cancer, Clinical medicine, Medical specialties, Hepatology, Hepatocellular carcinoma, Febrile neutropenia, Mapatumumab

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 05, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, announced updated data from its Phase 1 ADP-A2AFP trial for patients with liver cancer at ILCA.

Key Points: 
  • We are continuing the expansion phase and will update when new data becomes available.
  • Despite the recent advances, we need more and better systemic therapies for liver cancer, said Dr. Bruno Sangro of Clinica Universidad de Navarra.
  • The first results from this cell therapy trial are of great interest since they indicate obvious antitumor activity in some patients.
  • Dr. Bruno Sangro presented data from Cohort 3 and the expansion phase of the ADP-A2AFP Phase 1 trial during an oral presentation today at ILCA.

Global Deep Vein Thrombosis Market and Competitive Landscape 2021: Geographical Coverage Includes US, Germany, France, Italy, Spain, UK, Japan, Europe and Global - ResearchAndMarkets.com

Retrieved on: 
Monday, September 6, 2021
Health, Other Health, Hematology, Medical specialties, Clinical medicine, Venous thrombosis, Deep vein, Thrombosis

The "Global Deep Vein Thrombosis Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Deep Vein Thrombosis Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • The latest research provides comprehensive insights into Deep Vein Thrombosis pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following - Deep Vein Thrombosis treatment options, Deep Vein Thrombosis late-stage clinical trials pipeline, Deep Vein Thrombosis prevalence by countries, Deep Vein Thrombosis market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Deep Vein Thrombosis pipeline: Find out drugs in clinical trials for the treatment of Deep Vein Thrombosis by development phase 3, phase 2, by pharmacological class and company
    Deep Vein Thrombosis drugs: Identify key drugs marketed and prescribed for Deep Vein Thrombosis in the US, including trade name, molecule name, and company
    Deep Vein Thrombosis drugs sales: Find out the sales value for Deep Vein Thrombosis drugs by countries
    Deep Vein Thrombosis market valuations: Find out the market size for Deep Vein Thrombosis drugs in 2020 by countries.

The Worldwide Wireless Electrocardiography Device Industry is Expected to Reach $2.2+ Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, September 6, 2021
Medical Devices, Health, Mobile, Wireless, Technology, Cardiology, Medicine, Branches of biology, Clinical medicine, Cardiac electrophysiology, Electrodiagnosis, Electrocardiography, Electrophysiology, Science and technology in the Netherlands, Inductive charging, Wireless ambulatory ECG

Wireless Electrocardiography (ECG) Devices Market Analysis, By Type

Key Points: 
  • Wireless Electrocardiography (ECG) Devices Market Analysis, By Type
    Chapter 6.
  • Wireless Electrocardiography (ECG) Devices Market Analysis, By Modality
    Chapter 8.
  • Wireless Electrocardiography (ECG) Devices Market Analysis, By End User
    Chapter 9.
  • Wireless Electrocardiography (ECG) Devices Market Analysis, By Country
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210906005054/en/

New Study Investigates the Ability of Masimo ORi™ to Provide Early Warning of Hypoxemia During Endotracheal Intubation in ICU Patients

Retrieved on: 
Monday, September 6, 2021
Science, Health, Research, Medical Devices, Medicine, Clinical medicine, Medical specialties, Oxygen, Intensive care medicine, Respiratory therapy, Anesthesia, Masimo, Medical monitoring, Pulse oximetry, Monitoring, Mechanical ventilation

Noting the importance of optimizing preoxygenation in patients needing ETI, the researchers sought to evaluate whether ORi could provide early warning of impending hypoxemia during the procedure, because ORi supplies information beyond the range explored by SpO2.

Key Points: 
  • Noting the importance of optimizing preoxygenation in patients needing ETI, the researchers sought to evaluate whether ORi could provide early warning of impending hypoxemia during the procedure, because ORi supplies information beyond the range explored by SpO2.
  • Secondarily, the investigators evaluated whether a decline in ORi during preoxygenation predicted the occurrence of mild hypoxemia during ETI.
  • The inclusion criteria for this study were ICU admission with a need for ETI and an SpO2/FiO2 ratio above 214.
  • Oxygen reserve index for noninvasive early hypoxemia detection during endotracheal intubation in intensive care: the prospective observational NESOI study.

GeneQuantum and BrighGene sign agreement for development of antibody immune agonist conjugates

Retrieved on: 
Monday, September 6, 2021
Clinical medicine, Medicine, Cancer treatments, Antineoplastic drugs, Immunology, Biotechnology, Antibody-drug conjugate, Immune checkpoint, Monoclonal antibody therapy, Biopharmaceutical, Chemotherapy, Immune system

(hereinafter referred to as "BrighGene ") signed a co-development agreement for antibody immune agonist conjugate (AIAC), GQ1007.

Key Points: 
  • (hereinafter referred to as "BrighGene ") signed a co-development agreement for antibody immune agonist conjugate (AIAC), GQ1007.
  • In recent years, immunotherapeutic antibody drugs targeting PD-1 and PD-L1 (representing immune checkpoint inhibitors) have revolutionized cancer therapy.
  • Linker stability is extremely important in the field of antibody immune agonist conjugates.
  • GeneQuntum focuses on the development of differentiated innovation products through in-house research and development and diversified external research and development cooperation.

Glyscend Therapeutics Announces Preclinical Data at ADA 2021 on the Metabolic Benefits of its Oral Polymer-based Duodenal Exclusion Therapy

Retrieved on: 
Wednesday, August 4, 2021
Science, Other Science, Biotechnology, Research, Health, Diabetes, Dental, Clinical Trials, Medical specialties, Clinical medicine, Medicine, Digestive system surgery, Obesity, Bariatrics, Bariatric surgery, Diabetes

Glyscend Inc presented data during the American Diabetes Association 80th Scientific Sessions virtual meeting, June 25-29, 2021, from a study of its proprietary oral polymer duodenal exclusion therapy.

Key Points: 
  • Glyscend Inc presented data during the American Diabetes Association 80th Scientific Sessions virtual meeting, June 25-29, 2021, from a study of its proprietary oral polymer duodenal exclusion therapy.
  • The study evaluated the metabolic effects of its therapeutic (GLY-POL) in a non-obese T2D Goto-Kakizaki (GK) rat model, compared to control.
  • Similar reduction in PPG iAUC was evident during mixed meal tolerance testing (iAUC > 55%), suggesting that oral, polymer-based duodenal exclusion therapy is a viable method of improving glucose homeostasis.
  • Glyscend aims to replicate the beneficial effects of bariatric surgery via the duodenal exclusion mechanism, without the need for surgery.

Acadia Pharmaceuticals Reports Second Quarter 2021 Financial Results

Retrieved on: 
Wednesday, August 4, 2021
Biotechnology, Pharmaceutical, Health, Mental Health, Medical specialties, Clinical medicine, Medicine, Skeletal disorders, Arthritis, Acadia Pharmaceuticals, Osteoarthritis, Rett syndrome, Nasdaq

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2021.

Key Points: 
  • Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2021.
  • Completed enrollment of the Phase 3 LAVENDER study evaluating trofinetide for the treatment of Rett syndrome, with top-line results expected in the fourth quarter of 2021.
  • Initiated a Phase 2 study of ACP-044 for pain associated with osteoarthritis in the second quarter of 2021.
  • Acadia management will review its second quarter financial results and operations via conference call and webcast today at 4:30 p.m. Eastern Time.